跳至主要内容
临床试验/CTRI/2016/04/006854
CTRI/2016/04/006854进行中(未招募)4 期

A Prospective, Multicenter, Post-marketing Surveillance to Assess Safety of Zytiga�® (Abiraterone Acetate Tablets 250 mg) in IndianPatients With Metastatic, Castration-Resistant Prostate Cancer as Per Locally Approved Prescribing Information

Johnson Johnson Private Limited0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
进行中(未招募)

研究概览

简要总结

暂无简介。

研究设计

研究类型
Pms

入排标准

入选标准

  • Participants with established diagnosis of metastatic castration-resistant prostate carcinoma
  • Being newly initiated on Zytiga treatment (abiraterone acetate tablets 250 mg) based on independent clinical judgment of treating physicians as per locally approved prescribing information
  • Willing to provide written informed consent indicating that they understand the purpose and are willing to participate in the post-marketing
  • surveillance (PMS)

排除标准

  • Participants who are not eligible to receive Zytiga as per the locally approved prescribing information
  • Participants participating or planning to participate in any interventional drug trial during the course of this PMS
  • Contacts and

研究者

相似试验